DiaMedica Therapeutics thinks it has the data to get out from under a stubborn FDA clinical hold. Ten months after its phase 2/3 stroke clinical trial suffered the setback, the biotech is on the cusp of submitting evidence designed to explain the unexpected low blood pressure events and allay concerns.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,